Replies to post #10425 on Amarin Corp Plc (AMRN)

[KCSVEN]

I'm a typical middle child so generally I weigh both sides and make a decision, if everyone is on one side I will play devils advocate and take the other side to pull out more info even if I believe in the other position.

I am very willing to turn on management in companies I invest in but that usually means I will be selling. People that have a strong negative opinion of AMRN management should not own the stock, simple investing philosophy for me. Does not always work out but if you believe a company has poor management and you are correct you would do well over time not owning these companies.

I also rarely if ever have seen companies that put out press release on a regular basis to correct misinformation ever lead to any sustained price increase. If there is a direct report on the company-say fraud- then by all means address it as stock price would collapse related to a direct assault on the company. I do not believe in a recently launched biotech that short term price of the stock is a high priority for management, especially in a unique case like AMRN where the real launch happens with Anchor.

If AMRN went to zero the losses, though large, for me would no have a material effect on my life and happiness. I have not always invested where that is the case and understand the huge emotional strain losses take on people and he need to lame management ur the shorts or whatever.

Good news is piling up for AMRN and Vascepa
-main competitor linked to cancer-same studies show your product is not associated
-5 months to launch largest market of any drug since statins
-Large continued patent defense
-cash now at level can take until profitable with proper Anchor collaboration
-They can destroy Lovaza in 2014-with a smart sales force they could reach peak sales of 2 billion rapidly before reduce it
So you get 15-30 a share with a normalized P/E from Anchor depending on partnership details by end 2014 AND with cancer scare for Lovaza generics in marine likely wil not hurt Vascepa
If Reduce It is successful you have a 10 billion dollar drug, simple as that, your talking 100 a share with successful Reduce it.

I think management thinks that also which is why they need to do Anchor right as that gives them positive cash flow through to Reduce it results.

Also remember the new option for directors are at 5.60 price to execute, so if they want to make money on those they need price up.

Personally, I find management experienced and most of the time I find them highly competent and professional though I realize they have made some mistakes. To me good management and great product so until I feel that changes I will stay in the stock, simple as that